1. Animal models of ulcerative colitis and their application in drug research
- Author
-
Daren Low, Emiko Mizoguchi, and Deanna D Nguyen
- Subjects
Drug ,media_common.quotation_subject ,Drug Evaluation, Preclinical ,Pharmaceutical Science ,Review ,Disease ,Disease pathogenesis ,Inflammatory bowel disease ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,inflammatory bowel disease ,Drug Discovery ,Animals ,Humans ,Medicine ,Molecular Targeted Therapy ,preclinical trials ,030304 developmental biology ,Therapeutic strategy ,media_common ,Pharmacology ,0303 health sciences ,business.industry ,medicine.disease ,Ulcerative colitis ,Pathophysiology ,3. Good health ,Disease Models, Animal ,Drug Design ,030220 oncology & carcinogenesis ,Immunology ,emerging therapy ,Colitis, Ulcerative ,business - Abstract
The specific pathogenesis underlying inflammatory bowel disease is complex, and it is even more difficult to decipher the pathophysiology to explain for the similarities and differences between two of its major subtypes, Crohn's disease and ulcerative colitis (UC). Animal models are indispensable to pry into mechanistic details that will facilitate better preclinical drug/therapy design to target specific components involved in the disease pathogenesis. This review focuses on common animal models that are particularly useful for the study of UC and its therapeutic strategy. Recent reports of the latest compounds, therapeutic strategies, and approaches tested on UC animal models are also discussed.
- Published
- 2013
- Full Text
- View/download PDF